

Davide Melisi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4326106/davide-melisi-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

4,354
citations

33
h-index

60
g-index

185
ext. papers

5,538
ext. citations

5.3
avg, IF

5.51
L-index

#	Paper	IF	Citations
147	Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100400	3.6	2
146	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. 2022 , 10,		2
145	The Last Dance for Chemotherapy Intensification in Non-Asian Advanced Biliary Tract Cancers?. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102509	2.2	1
144	Micro-RNA in Cholangiocarcinoma: Implications for Diagnosis, Prognosis, and Therapy. <i>Journal of Molecular Pathology</i> , 2022 , 3, 88-103	0.4	1
143	A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements. <i>Blood</i> , 2021 , 138, 3656-3656	2.2	
142	Target Therapy and Immunotherapy in Gastric Cancer. <i>Updates in Surgery Series</i> , 2021 , 225-233	0.1	
141	The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting. <i>Cancer Management and Research</i> , 2021 , 13, 7747-7757	3.6	1
140	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. <i>Frontiers in Oncology</i> , 2021 , 11, 6383605.3		11
139	Safety and activity of the TGF β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer 2021 , 9,		29
138	Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. <i>Future Oncology</i> , 2021 , 17, 1843-1854	3.6	2
137	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. <i>Current Drug Targets</i> , 2021 , 22, 1021-1033	3	2
136	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 150, 155-167	7.5	15
135	Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. <i>Oncology and Therapy</i> , 2021 , 9, 557-573	2.7	2
134	Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. <i>Future Oncology</i> , 2021 , 17, 389-402	3.6	17
133	Clinicogenomic Analysis of -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. <i>Cancer Discovery</i> , 2021 , 11, 326-339	24.4	45
132	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. <i>ESMO Open</i> , 2021 , 6, 100032	6	7
131	The Multifaceted Role of TGF β in Gastrointestinal Tumors. <i>Cancers</i> , 2021 , 13,	6.6	4

130	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		2
129	Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma. <i>Hepatology</i> , 2021 , 74, 3235-3248	11.2	3
128	Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. <i>Pancreatology</i> , 2021 ,	3.8	3
127	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
126	Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 ,	4.2	1
125	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 308	5.7	5
124	Permissive State of EMT: The Role of Immune Cell Compartment. <i>Frontiers in Oncology</i> , 2020 , 10, 587	5.3	9
123	Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5325-5334	3.1	10
122	Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	5
121	Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4661-4669	12.9	7
120	Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. <i>European Journal of Cancer</i> , 2020 , 135, 159-169	7.5	9
119	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2020 , 21, 671-684	21.7	402
118	Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919890281	5.4	5
117	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. <i>ESMO Open</i> , 2020 , 5,	6	20
116	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , 2020 , 9,	7.9	14
115	Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. <i>Abdominal Radiology</i> , 2020 , 45, 3809-3818	3	5
114	The Role of Anti-Angiogenics in Pre-Treated Metastatic -Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020 , 12,	6.6	9
113	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020 , 8,	5.3	4

112	Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion. <i>Blood</i> , 2020 , 135, 2071-2084	2.2	25
111	Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16769-e16769	2.2	1
110	Biliary tract cancer (BTC) in the elderly: A real-world tertiary cancer center experience.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 492-492	2.2	1
109	Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 660-660	2.2	3
108	The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: The need trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e18508-e18508	2.2	
107	A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4664-TPS4664	2.2	
106	Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 247-257	6.1	22
105	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. <i>Hepatology</i> , 2020 , 72, 982-996	11.2	21
104	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020 , 40, 704-711	7.9	25
103	A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920937889	5.4	15
102	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with rearrangements. <i>Future Oncology</i> , 2020 , 16, 2385-2399	3.6	39
101	HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. <i>Cancers</i> , 2020 , 12,	6.6	9
100	KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 227	12.8	18
99	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920947969	5.4	4
98	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020 , 25, 780-786	5.7	5
97	Gastric cancer: Translating novels concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101889	14.4	39
96	Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor- β inhibitor galunisertib in patients with pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 1003-1015	3.5	8
95	TGF β receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 975-991	3.5	36

94	Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2019 , 154, 932-942	5.4	55
93	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. <i>European Journal of Cancer</i> , 2019 , 117, 84-90	7.5	13
92	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2019 , 79, 5612-5625	10.1	8
91	NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 144, 102826	7	11
90	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4124-4124	2.2	22
89	Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS462-TPS462	2.2	4
88	Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2019 , 19, 375-392	3.2	6
87	The Vasculopathy in the Bone Marrow Microenvironment of Humanized Sickle Cell Mice Is Reversible By Blood Transfusion. <i>Blood</i> , 2019 , 134, 2256-2256	2.2	
86	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 591-597	3.6	4
85	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 1479-1482	3.6	4
84	Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2019 , 106, 24-33	7.5	24
83	Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. <i>Hpb</i> , 2019 , 21, 596-603	3.8	20
82	Noncoding RNA in Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2019 , 39, 13-25	7.3	26
81	Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. <i>Pancreatology</i> , 2018 , 18, 420-428	3.8	23
80	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 161-175	3.5	12
79	Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. <i>European Journal of Clinical Nutrition</i> , 2018 , 72, 772-779	5.2	18
78	Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 357-370	3.8	3
77	Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	76

76	The curious case of G α s gain-of-function in neoplasia. <i>BMC Cancer</i> , 2018 , 18, 293	4.8	14
75	CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. <i>Anticancer Research</i> , 2018 , 38, 4889-4895	2.3	21
74	Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. <i>Journal of Translational Medicine</i> , 2018 , 16, 219	8.5	63
73	MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. <i>Anticancer Research</i> , 2018 , 38, 1937-1946	2.3	20
72	Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. <i>International Journal of Obesity</i> , 2018 , 42, 334-343	5.5	22
71	Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis. <i>Antioxidants and Redox Signaling</i> , 2018 , 28, 1-14	8.4	22
70	Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. <i>Nature Communications</i> , 2018 , 9, 5193	17.4	31
69	Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	23
68	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1208-1214	8.7	111
67	Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis. <i>Case Reports in Oncology</i> , 2018 , 11, 615-621	1	19
66	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 115, 1-12	7	20
65	A circulating T2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. <i>Onc Immunology</i> , 2017 , 6, e1322242	7.2	23
64	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. <i>British Journal of Cancer</i> , 2017 , 116, 1247-1253	8.7	21
63	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2017 , 23, 4312-4322	12.9	27
62	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017 , 20, 825-833	7.6	24
61	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2575-2583	12.9	10
60	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017 , 13, 2265-2275	3.6	8
59	Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. <i>Data in Brief</i> , 2017 , 15, 376-381	1.2	

58	Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 187-188	2.8	
57	Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?. <i>ESMO Open</i> , 2017 , 2, e000206	6	29
56	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017 , 22, 1463-1469	5.7	17
55	Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension. <i>Free Radical Biology and Medicine</i> , 2017 , 112, 376-386	7.8	19
54	TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. <i>Drug Resistance Updates</i> , 2017 , 33-35, 36-42	23.2	26
53	EMT and Treatment Resistance in Pancreatic Cancer. <i>Cancers</i> , 2017 , 9,	6.6	83
52	Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A REAL LIFE study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 396-396	2.2	2
51	Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor- β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TP3501-TP3501	2.2	3
50	Molecular Markers in the Prediction of Response to Neoadjuvant Treatments in Esophagogastric Junction Adenocarcinoma 2017 , 85-94		
49	An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 6164-6175	12.9	48
48	IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF- κ B Activation. <i>Clinical Cancer Research</i> , 2016 , 22, 1432-44	12.9	66
47	Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC) 2016 ,		9
46	A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4019-4019	2.2	26
45	Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4124-4124	2.2	5
44	Resistance to ALK Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016 , 147-163	0.3	1
43	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15732-e15732	2.2	
42	Combined inhibition of IL1, CXCR1/2, and TGF β signaling pathways modulates in-vivo resistance to anti-VEGF treatment. <i>Anti-Cancer Drugs</i> , 2016 , 27, 29-40	2.4	25
41	Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus. <i>Journal of Physical Education and Sports Management</i> , 2016 , 2, a000620	2.8	4

40	242P Effects of nal-IRI (MM-398) + 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1. <i>Annals of Oncology</i> , 2016 , 27,	10.3	2
39	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016 , 139, 2859-2864	7.5	57
38	TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. <i>British Journal of Cancer</i> , 2015 , 113, 878-85	8.7	25
37	2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts). <i>European Journal of Cancer</i> , 2015 , 51, S445	7.5	5
36	Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. <i>International Journal of Oncology</i> , 2015 , 46, 1099-108	4.4	35
35	Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 412-412	2.2	3
34	Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A Real-life study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 424-424	2.2	9
33	An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. <i>Oncotarget</i> , 2015 , 6, 13822-34	3.3	36
32	Current Strategies to Overcome Resistance to ALK-Inhibitor Agents. <i>Current Drug Metabolism</i> , 2015 , 16, 585-96	3.5	12
31	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4788-801	5.6	48
30	FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 372-372	2.2	
29	Toll-Like Receptor 9 Agonists for Cancer Therapy. <i>Biomedicines</i> , 2014 , 2, 211-228	4.8	22
28	Spray deposited carbon nanotubes for organic vapor sensors. <i>Microelectronics Journal</i> , 2014 , 45, 1691-1694	2.8	6
27	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 535-49	4.1	22
26	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , 2014 , 5, 2839-52	3.3	134
25	Pancreatic cancer: systemic combination therapies for a heterogeneous disease. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6660-9	3.3	31
24	Rationale and clinical use of multitargeting anticancer agents. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 536-42	5.1	27
23	Radiation detectors based on Multiwall Carbon Nanotubes deposited by a spray technique. <i>Thin Solid Films</i> , 2013 , 543, 19-22	2.2	14

22	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. <i>Frontiers in Pharmacology</i> , 2013 , 4, 56	5.6	66
21	Activity of nab-paclitaxel (nab-P) monotherapy in heavily pretreated pancreatic cancer (aPDAC) patients (pts): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15057-e15057 ^{2,2}		
20	NF- κ B as a target for pancreatic cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16 Suppl 2, S1-10	6.4	74
19	Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14661-e14661	2.2	1
18	Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. <i>Clinical Cancer Research</i> , 2011 , 17, 5822-32 ^{12.9}		73
17	Emerging pathways and future targets for the molecular therapy of pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 1183-96	6.4	42
16	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. <i>Clinical Cancer Research</i> , 2011 , 17, 6531-41	12.9	42
15	Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1190-204	9.7	120
14	Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. <i>Molecular Cancer Research</i> , 2009 , 7, 624-33	6.6	65
13	Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. <i>Clinical Cancer Research</i> , 2009 , 15, 6367-77	12.9	34
12	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 829-40	6.1	247
11	Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. <i>Clinical Cancer Research</i> , 2008 , 14, 5069-80	12.9	127
10	NF-kappa B as a target for cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 133-44	6.4	79
9	Key cancer cell signal transduction pathways as therapeutic targets. <i>European Journal of Cancer</i> , 2006 , 42, 290-4	7.5	118
8	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. <i>Endocrine-Related Cancer</i> , 2005 , 12, 1051-8	5.7	30
7	Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. <i>Clinical Cancer Research</i> , 2005 , 11, 5639-44	12.9	79
6	Angiogenesis: a target for cancer therapy. <i>Current Pharmaceutical Design</i> , 2004 , 10, 11-26	3.3	61
5	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to anti-epidermal growth factor receptor therapy. <i>Clinical Cancer Research</i> , 2004 , 10, 784-93	12.9	309

4	Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. <i>Endocrine-Related Cancer</i> , 2004 , 11, 51-68	5.7	27
3	Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 677-88	6.1	26
2	Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. <i>Clinical Cancer Research</i> , 2003 , 9, 1566-72	12.9	87
1	Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. <i>Clinical Cancer Research</i> , 2001 , 7, 4156-63	12.9	32